Confused Connections? Targeting White Matter to Address Treatment Resistant Schizophrenia.
Ontology highlight
ABSTRACT: Despite development of comprehensive approaches to treat schizophrenia and other psychotic disorders and improve outcomes, there remains a proportion (approximately one-third) of patients who are treatment resistant and will not have remission of psychotic symptoms despite adequate trials of pharmacotherapy. This level of treatment response is stable across all stages of the spectrum of psychotic disorders, including early phase psychosis and chronic schizophrenia. Our current pharmacotherapies are beneficial in decreasing positive symptomology in most cases, however, with little to no impact on negative or cognitive symptoms. Not all individuals with treatment resistant psychosis unfortunately, even benefit from the potential pharmacological reductions in positive symptoms. The existing p
SUBMITTER: Crocker CE
PROVIDER: S-EPMC6201564 | biostudies-literature | 2018
REPOSITORIES: biostudies-literature
ACCESS DATA